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Guidelines for Inclusion of Patient-Reported Outcomes
in Clinical Trial Protocols
The SPIRIT-PRO Extension
Melanie Calvert, PhD; Derek Kyte, PhD; Rebecca Mercieca-Bebber, PhD; Anita Slade, PhD;
An-Wen Chan, MD, DPhil; Madeleine T. King, PhD; and the SPIRIT-PRO Group
IMPORTANCE Patient-reported outcome (PRO) data from clinical trials can provide valuable
evidence to inform shared decisionmaking, labeling claims, clinical guidelines, and health
policy; however, the PRO content of clinical trial protocols is often suboptimal. The SPIRIT
(Standard Protocol Items: Recommendations for Interventional Trials) statement was
published in 2013 and aims to improve the completeness of trial protocols by providing
evidence-based recommendations for theminimum set of items to be addressed, but it does
not provide PRO-specific guidance.
OBJECTIVE To develop international, consensus-based, PRO-specific protocol guidance
(the SPIRIT-PRO Extension).
DESIGN, SETTING, AND PARTICIPANTS The SPIRIT-PROExtensionwas developed following the
EnhancingQuality and Transparency of Health Research (EQUATOR) Network’smethodological
framework for guideline development. This included (1) a systematic review of existing
PRO-specific protocol guidance to generate a list of potential PRO-specific protocol items
(published in 2014); (2) refinements to the list and removal of duplicate items by the
International Society for Quality of Life Research (ISOQOL) Protocol Checklist Taskforce;
(3) an international stakeholder survey of clinical trial research personnel, PROmethodologists,
health economists, psychometricians, patient advocates, funders, industry representatives,
journal editors, policymakers, ethicists, and researchers responsible for evidence synthesis
(distributed by 38 international partner organizations in October 2016); (4) an international
Delphi exercise (n = 137 invited; October 2016 to February 2017); and (5) consensusmeeting
(n = 30 invited;May 2017). Prior to voting, consensusmeeting participants were informed of
the results of the Delphi exercise and given data from structured reviews evaluating the PRO
protocol content of 3 defined samples of trial protocols.
RESULTS The systematic review identified 162 PRO-specific protocol recommendations
from 54 sources. The ISOQOL Taskforce (n = 21) reduced this to 56 items, which were
considered by 138 international stakeholder survey participants and 99 Delphi panelists.
The final wording of the SPIRIT-PRO Extension was agreed on at a consensus meeting
(n = 29 participants) and reviewed by external group of experts during a consultation period.
Eleven extensions and 5 elaborations to the SPIRIT 2013 checklist were recommended for
inclusion in clinical trial protocols in which PROs are a primary or key secondary outcome.
Extension items focused on PRO-specific issues relating to the trial rationale, objectives,
eligibility criteria, concepts used to evaluate the intervention, time points for assessment,
PRO instrument selection andmeasurement properties, data collection plan, translation to
other languages, proxy completion, strategies to minimize missing data, and whether PRO
data will be monitored during the study to inform clinical care.
CONCLUSIONS AND RELEVANCE The SPIRIT-PRO guidelines provide recommendations for
items that should be addressed and included in clinical trial protocols in which PROs are a
primary or key secondary outcome. Improved design of clinical trials including PROs could
help ensure high-quality data that may inform patient-centered care.
JAMA. 2018;319(5):483-494. doi:10.1001/jama.2017.21903
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C linical trial protocols are essential documents thatdescribe the study design and conduct. A protocolshould provide sufficient detail to enable funders,
reviewers, and ethics committees to appraise the scientific,
methodological, and ethical rigor of the trial and for the research
team to conduct a high-quality study.1,2 Although trial protocols
serve as the foundation for study planning, conduct, reporting,
and appraisal, they vary greatly in content and quality.1,2 To
address this issue, the SPIRIT (Standard Protocol Items: Recom-
mendations for Interventional Trials) statement was published in
2013.1,2 SPIRIT provides an evidence-based list of items recom-
mended for inclusion in trial protocols. It does not, however, pro-
vide specific guidance on protocol content relating to patient-
reported outcomes (PROs), such as health-related quality of life
or patient-reported symptoms.
The importance of PROs has been recognized by major inter-
national health policy and regulatory authorities and patients.3-5
Patient-reported outcome results of trials, if captured in a scientifi-
cally rigorous way, may inform clinical decision making,6 pharma-
ceutical labeling claims,4,5 and product reimbursement and influ-
ence health care policy.6 Despite this, the quality of PRO content in
many protocols is often suboptimal, regardless of the degree of
adherence to SPIRIT.7-9 Because PROs are intrinsically subjective
and require completion by patients within a specific time frame,
they present a range of scientific and logistical challenges for
researchers.10-12 Comprehensive planning and instruction in the
protocol can mitigate many PRO-specific issues through trial con-
duct and subsequent analysis and reporting. Protocol developers,
particularly those not familiar with PRO methodology, may benefit
from explanation of PRO-specific aspects to facilitate improve-
ments in content.
The aim of this international project was to develop an
evidence-based extension of the SPIRIT 2013 statement, identify-
ing additional PRO items recommended for inclusion in clinical
trial protocols (extensions), and to elaborate on the existing
SPIRIT 2013 statement specif ical ly as appl ied to PROs
(elaborations).13 This Special Communication describes the meth-
ods used to gain consensus on each additional SPIRIT-PRO
extension/elaboration, provides a brief explanatory rationale, and
includes PRO-specific items that may be included in supplemental
trial documents.
SPIRIT-PRO Development Methods
The SPIRIT-PRO Extension was developed according to the
Enhancing Quality and Transparency of Health Research
(EQUATOR) Network’s methodological framework for guideline
development (eFigure 1 in Supplement 1).14 This included a system-
atic review of existing PRO-specific protocol guidance,15 a stake-
holder survey of a group of international experts, and a Delphi exer-
cise and consensus meeting, followed by consultation on the final
SPIRIT-PRO Extension.14 The systematic review comprised a search
of the MEDLINE, EMBASE, CINHAL, and Cochrane Library data-
bases (inception to February 2013) using the key words patient-
reported outcomes or health-related quality of life in combination
with guidance, guidelines, or checklist. Further guidance docu-
ments were identified via Google, Google Scholar, requests to
members of the UK Clinical Research Collaboration registered clini-
cal trials units, international experts, and citation and reference
searches of included articles. Articles were deemed eligible if they
contained guidance, a checklist, or both regarding PRO-related trial
protocol content.15
eFigure 1 in Supplement 1 summarizes themethodsandpartici-
pants involved in the development of SPIRIT-PRO, the numbers of
candidate items considered at each step, and the flow toward the
final set of items included in SPIRIT-PRO. TheeTable in Supplement
1 outlines the participant characteristics. Patient partners contrib-
uted to theco-designof the researchandgrantapplicationandhave
provided input throughout the study.
Ethical Review of Study
Ethical approval was provided by the University of Birmingham
Ethical Review Board ( ERN_16-0819). Participant information
was provided to potential participants electronically prior to sur-
vey completion and in advance of the consensus meeting. Survey
participants provided electronic informed consent, and written
consent was provided by the consensus meeting participants.
Systematic Reviewof ExistingPRO-Specific Protocol Guidance
andDevelopment of theDelphi andStakeholder Survey
Our systematic review of existing PRO protocol guidance
identified 162 PRO-specific protocol recommendations from
54 sources, such as the need to specify the timing of PRO
assessment, the provision of PRO data collection and analyses
plans, and specification/justif ication for the chosen PRO
questionnaire.15 The International Society for Quality of Life
Research (ISOQOL) Protocol Checklist Taskforce comprising inter-
national experts in PROs research and clinical trials (eTable and
eAppendix in Supplement 1) reduced this list to 56 candidate
items by removing or merging duplicate items, meaning that 56
items were included in the subsequent identical stakeholder and
Delphi surveys. Survey participants were asked to rate the impor-
tance of including each of the 56 candidate items in the final
SPIRIT-PRO Extension using a 9-point scale ranging from not
important (1-3) to important but not critical (4-6) and critical
(7-9). Respondents provided separate ratings according to
whether a PRO was included as a primary vs secondary outcome
in a trial.
International Stakeholder Survey
In 2016, an anonymized online international stakeholder survey
was conducted targeting clinical trial research personnel, PRO
Key Points
Question What information should be included in a clinical trial
protocol when a patient-reported outcome (PRO) is a primary or
key secondary outcome?
Findings Following an international consensus development
process using the Enhancing Quality and Transparency of Health
Research (EQUATOR) methodology, 16 PRO-specific items were
recommended for inclusion in clinical trial protocols.
Meaning Inclusion of these items in clinical trial protocols may
help improve the quality of PRO data.
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methodologists, health economists, psychometricians, patient
advocates, funders, industry representatives, journal editors,
policy makers, ethicists, and researchers responsible for evi-
dence synthesis. Respondents were self-selected volunteers
from a sample of eligible individuals recruited via 38 interna-
tional partner organizations (listed in the eAppendix in Supple-
ment 1). From these organizations, 138 participants provided ano-
nymized survey results, which informed round 2 of the Delphi
panel exercise.
International Delphi Exercise
In parallel with the international stakeholder survey, 114 key
experts from the ISOQOL Protocol Checklist Taskforce, interna-
tional partner organizations, and other experts known or recom-
mended to the SPIRIT-PRO Executive (eAppendix in Supplement 1)
were invited to join an international, multidisciplinary expert
Delphi panel. Delphi panelists were advised not to complete the
stakeholder survey to avoid double counting of results. Ninety-
nine Delphi panelists completed 2 rounds of online surveys, and
results informed the subsequent international consensus meeting.
Data collected from the stakeholder and round 1 Delphi surveys
were anonymized, and the item-level results were provided to the
Delphi panel for consideration prior to voting in Delphi round 2.
Further details and the results of the Delphi and stakeholder sur-
veys are available on the study website.16
ConsensusMeeting
Using the results from the stakeholder survey and Delphi proc-
ess, the SPIRIT-PRO Operations Team (M.C., D.K., R.M.B., A.S.,
and M.K.) mapped the 56 candidate SPIRIT-PRO items to corre-
sponding SPIRIT-2013 items, revising wording as needed to
address stakeholder/Delphi panelist comments. For each candi-
date SPIRIT-PRO item, the Operations Team presented the con-
sensus meeting delegates with recommendations for SPIRIT
elaborations and extensions (see Box for definitions) based on a
decision tree (eFigure 2 in Supplement 1) that incorporated infor-
mation drawn from the Delphi survey and 3 separate reviews of
PRO protocol content (n = 207 protocols): protocols from the UK
National Institute for Health Research (NIHR) Health Technology
Assessment program7; cancer trial protocols from the NIHR8; and
international ovarian cancer protocols.9 Twenty-nine participants
purposively sampled from the Delphi panel attended the 2-day
consensus meeting hosted by the University of Birmingham in
May 2017 (eTable in Supplement 1). The meeting was designed to
Box. Glossary
SPIRIT: Standard Protocol Items: Recommendations for
Interventional Trials1,2
SPIRIT-PRO Extension item: an additional checklist item describing
PRO protocol content to address an aspect of PRO assessment that
is not adequately covered by SPIRIT, as judged by available evidence
and expert opinion
SPIRIT Elaboration item: an elaboration of an existing SPIRIT item as
applied to a specific context; in this instance, as applied to clinical
trials assessing PROs
Patient-reported outcome (PRO): an outcome reported directly
by patients themselves and not interpreted by an observer;
PROsmay include patient assessments of health status, quality of
life, or symptoms17
Proxy-reported outcome: “a measurement based on a report
by someone other than the patient reporting as if he or she
is the patient”4
Health-related quality of life: “a multidimensional concept that
usually includes self-report of the way in which physical, emotional,
social, or other domains of well-being are affected by a disease
or its treatment”17
Primary outcome/end point: themost important outcome in a trial,
providing themost clinically relevant evidence directly related to the
primary objective of the trial
Secondary outcomes/end point(s): outcomes prespecified in the
protocol to assess additional effects of the intervention; some PROs
may be identified as important or key secondary outcomes
Important or key secondary PROs/end points: Some PROmeasures
(particularly health-related quality-of-life measures) are
multidimensional, producing several domain-specific outcome
scales; eg, pain, fatigue, physical function, psychological distress.
For any particular trial, it is likely that a particular PRO or
PRO domain(s) will be more relevant than others, reflecting the
expected effect(s) of the trial intervention(s) in the target patient
population. These relevant PRO(s) and/or domain(s) may
additionally constitute the important or key secondary PROs
(identified a priori and specified as such in the trial protocol and
statistical analysis plan) and will be the focus of hypothesis testing.
In a regulatory environment, these outcomesmay support a labeling
claim. Because these outcomes are linked with hypotheses
(CONSORT PRO Extension 2b),17 theymay be subject to P-value
adjustment (or “α spending”). Patient-reported outcomes not only
may provide evidence of efficacy/effectiveness but also may be
intended to capture and provide evidence of safety and tolerability
(eg, PRO-CTCAE).18
Concept: “The specific measurement goal (ie, the thing that
is to bemeasured by a PRO instrument). In clinical trials, a PRO
instrument can be used tomeasure the effect of a medical
intervention on one or more concepts. PRO concepts represent
aspects of how patients function or feel related to a health
condition or its treatment.”4
Domain: “A subconcept represented by a score of an instrument
that measures a larger concept comprised of multiple domains.
For example, psychological function is the larger concept containing
the domains subdivided into items describing emotional function
and cognitive function.”4
Instrument: “Ameans to capture data (eg, a questionnaire) plus
all the information and documentation that supports its use.
Generally, that includes clearly definedmethods and instructions
for administration or responding, a standard format for data
collection, and well-documentedmethods for scoring, analysis,
and interpretation of results in the target patient population.”4
Item: “an individual question, statement, or task (and its
standardized response options) that is evaluated by the patient
to address a particular concept”4
Timewindow: a predefined time frame before and after the
protocol-specified PRO assessment time point whereby the result
would still be deemed to be clinically relevant19
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seek consensus on the content of the SPIRIT-PRO Extension.
Meeting participants were invited to consider the focus of the
guidance and agreed that it should apply to trials in which PROs
are a primary or key secondary outcome (as defined in the glos-
sary [Box]). Delegates anonymously voted using Turning Point)/
Responseware software, version 5.1 (Turning Technologies LLC),
to (1) include the candidate item as recommended; (2) exclude
the item; (3) or initiate further discussion. Key research evidence
(round 2 Delphi survey results and systematic review data) pre-
sented to meeting participants is available in Supplement 2.
Consensus meeting participants were also invited to review
Delphi results for recommendation on where to include each of
the candidate items in addition to or instead of the trial protocol
(eg, guidance/training for trial staff, information/guidance for
study participants, or the statistical analysis plan).
Final Consultation
Following the consensus meeting, attendees commented
on wording and agreed on the penultimate SPIRIT-PRO Exten-
sion content. Broader feedback on the final guidance was
sought from the Delphi panel and international partners during a
3-week consultation period. Final edits in response to feedback
were made by the Operations Team and agreed on by the SPIRIT-
PRO Group.
Results
SPIRIT-PRO Checklist Items and Explanation
The final SPIRIT-PRO Extension recommends that, in conjunction
with existing SPIRIT 2013 items, 16 items (11 extensions and
5 elaborations) should be routinely addressed in all clinical trial
protocols in which PROs are a primary or key secondary outc-
ome. Further information regarding the SPIRIT 2013 items has
been published by Chan et al.1,2 The Table lists the items of the
SPIRIT 2013 checklist and the SPIRIT-PRO extensions and elab-
orations. In total, the 11 extensions and 5 elaborations incorpo-
rated content from 34 of the original 56 candidate items, com-
prising 27 items that were merged during the consensus meeting
and a further 7 items that remained unchanged. One new item,
SPIRIT-18a(iii)-PRO Extension, was generated through discussion.
Definitions of key terms are contained in the glossary (Box).
A brief explanation for each PRO extension or elaboration is in-
cluded herein, with references to supporting empirical evidence
when available (items 6a through 22). Item 5a was not supported
by empirical evidence but was supported by expert opinion drawn
fromour systematic review of PROprotocol guidance15 and, in line
with the development of the original SPIRIT statement,1,2 was un-
derpinned by a strong pragmatic rationale.
Administrative Information
SPIRIT-5a-PROElaboration: Specify the individual(s) responsible
for the PRO content of the trial protocol.
Explanation: Providing information (eg, name, affiliation,
contact details) on who wrote the PRO-specific aspects of the
trial protocol promotes transparency and accountability and iden-
tifies the appropriate point of contact for resolution of any PRO-
specific queries. When patients have actively contributed to this
process, this should be documented as per recent guidance for
the reporting of patient and public involvement.21
SPIRIT-6a-PRO Extension: Describe the PRO-specific re-
search question and rationale for PRO assessment and summa-
rize PRO findings in relevant studies.
Explanation: InclusionofPROs in a trial requires careful consid-
eration and planning. A clearly defined question helps with selec-
tionofmeasures and specificationof hypotheses andanalyses. Evi-
dencesuggests thatmany trials includePROswithout specifying the
PRO-specific research question and without a rationale or any ref-
erence to PROs in related studies.7-9 Consequently, staff and pa-
tientsmaynotunderstandwhyPROsarebeing assessed, andmiss-
ingdatamayresult.7-12WhenthePROisasecondaryoutcome,abrief
rationale may be adequate.
SPIRIT-7-PRO Extension: State specific PRO objectives
or hypotheses (including relevant PRO concepts/domains).
Explanation: PRO measures may be multidimensional (eg,
health-related quality of life) or unidimensional (eg, specific symp-
toms such as pain), and assessments may be scheduled at several
timepointsduringa trial. Prespecificationofobjectivesandhypoth-
esesencourages identificationof keyPROdomainsand timepoints,
reducing the risk ofmultiple statistical testing and selective report-
ing of PROs based on statistically significant results (see also PRO
elaboration 20a below).4
Methods: Participants, Interventions, and Outcomes
SPIRIT-10-PROExtension: Specify anyPRO-specific eligibility cri-
teria (eg, language/reading requirements or prerandomization22
completion of PRO). If PROswill not be collected from the entire
studysample,providea rationaleanddescribe themethodforob-
taining the PRO subsample.
Explanation:AnyPRO-specific eligibility criteria shouldbe con-
sidered at the design stage of the trial and clearly specified in the
protocol. In large trials, sufficient power may be achieved by col-
lecting PROs from a representative subset of participants, while in
some trials itmaynotbepossible to collectPROs in theentirepopu-
lation (eg, because of nonavailability of validated questionnaires in
all languages)8; in such instances, the rationale for the sampling
method should be described.
SPIRIT-12-PRO Extension: Specify the PRO concepts/
domains used to evaluate the intervention (eg, overall health-
related quality of life, specific domain, specific symptom)
and, for each one, the analysis metric (eg, change from baseline,
final value, time to event) and the principal time point or period
of interest.
Explanation: The PRO concepts/domains and time points for
assessment should closely align with the trial objectives and
hypotheses. Because of the risk of multiple statistical testing, the
domain(s) and principal time point(s) for analyses should be
specified a priori.4,23
SPIRIT-13-PRO Extension: Include a schedule of PRO assess-
ments, providing a rationale for the time points, and justifying if
the initial assessment is not prerandomization. Specify timewin-
dows,whetherPROcollection isprior toclinical assessments, and,
if usingmultiple questionnaires,whether order of administration
will be standardized.
Explanation:Provision of an easy-to-follow schedulewill assist
staff andmayhelp reducemissingdata.22 CollectingPROdataprior
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Table. SPIRIT 2013 and SPIRIT-PRO Extension Checklist: Recommended Items to Address in a Clinical Trial Protocola
SPIRIT Section
SPIRIT
Item No. SPIRIT Item Description
SPIRIT-PRO
Item No.
SPIRIT-PRO Extension
or Elaboration Item Description
Addressed
on Page No.b
Administrative Information
Title 1 Descriptive title identifying
the study design, population,
interventions, and, if applicable,
trial acronym
Trial registration 2a Trial identifier and registry name
(if not yet registered,
name of intended registry)
2b All items from the World Health
Organization Trial Registration
Data Set
Protocol version 3 Date and version identifier
Funding 4 Sources and types of financial,
material, and other support
Roles and
responsibilities
5a Names, affiliations, and roles
of protocol contributors
SPIRIT-
5a-PRO
Elaboration
Specify the individual(s) responsible
for the PRO content of the
trial protocol.
5b Name and contact information
for the trial sponsor
5c Role of study sponsor and funders,
if any, in study design; collection,
management, analysis, and
interpretation of data; writing
of the report; and the decision
to submit the report for publication,
including whether they will have
ultimate authority over any
of these activities
5d Composition, roles, and responsibilities
of the coordinating center,
steering committee, end-point
adjudication committee, data
management team, and other
individuals or groups overseeing
the trial, if applicable (see item 21a
for data monitoring committee)
Introduction
Background and
rationale
6a Description of research question
and justification for undertaking
the trial, including summary
of relevant studies (published
and unpublished) examining
benefits and harms
for each intervention
SPIRIT-
6a-PRO
Extension
Describe the PRO-specific research
question and rationale for PRO
assessment and summarize PRO
findings in relevant studies.
6b Explanation for choice
of comparators
Objectives 7 Specific objectives or hypotheses SPIRIT-
7-PRO
Extension
State specific PRO objectives
or hypotheses (including relevant PRO
concepts/domains).
Trial design 8 Description of trial design,
including type of trial (eg, parallel
group, crossover, factorial,
single group), allocation ratio,
and framework (eg, superiority,
equivalence, noninferiority,
exploratory)
Methods: Participants, Interventions, and Outcomes
Study setting 9 Description of study settings
(eg, community clinic, academic
hospital) and list of countries
where data will be collected;
reference to where list
of study sites can be obtained
Eligibility criteria 10 Inclusion and exclusion criteria
for participants; if applicable,
eligibility criteria for study centers
and individuals who will perform
the interventions (eg, surgeons,
psychotherapists)
SPIRIT-
10-PRO
Extension
Specify any PRO-specific eligibility criteria
(eg, language/reading requirements or
prerandomization completion of PRO).
If PROs will not be collected from the entire
study sample, provide a rationale and
describe the method for obtaining
the PRO subsample.
(continued)
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Table. SPIRIT 2013 and SPIRIT-PRO Extension Checklist: Recommended Items to Address in a Clinical Trial Protocola (continued)
SPIRIT Section
SPIRIT
Item No. SPIRIT Item Description
SPIRIT-PRO
Item No.
SPIRIT-PRO Extension
or Elaboration Item Description
Addressed
on Page No.b
Interventions 11a Interventions for each group
with sufficient detail to allow replication,
including how and when they
will be administered
11b Criteria for discontinuing or modifying
allocated interventions for a given trial
participant (eg, drug dose change in
response to harms, participant request,
or improving/worsening disease)
11c Strategies to improve adherence to
intervention protocols and any procedures
for monitoring adherence (eg, drug tablet
return, laboratory tests)
11d Relevant concomitant care and
interventions that are permitted or
prohibited during the trial
Outcomes 12 Primary, secondary, and other outcomes,
including the specific measurement
variable (eg, systolic blood pressure),
analysis metric (eg, change from baseline,
final value, time to event), method of
aggregation (eg, median, proportion),
and time point for each outcome;
explanation of the clinical relevance
of chosen efficacy and harm outcomes
is strongly recommended
SPIRIT-
12-PRO
Extension
Specify the PRO concepts/domains used to
evaluate the intervention (eg, overall
health-related quality of life, specific
domain, specific symptom) and,
for each one, the analysis metric
(eg, change from baseline, final value, time
to event) and the principal time point or
period of interest.
Participant
timeline
13 Time schedule of enrollment,
interventions (including any run-ins
and washouts), assessments, and visits
for participants; a schematic diagram
is highly recommended (see figure
in Chan et al1,2)
SPIRIT-
13-PRO
Extension
Include a schedule of PRO assessments,
providing a rationale for the time points,
and justifying if the initial assessment is not
prerandomization. Specify time windows,
whether PRO collection is prior to clinical
assessments, and, if using multiple
questionnaires, whether order of
administration will be standardized.
Sample size 14 Estimated number of participants
needed to achieve study objectives
and how it was determined, including
clinical and statistical assumptions
supporting any sample size calculations
SPIRIT-
14-PRO
Elaboration
When a PRO is the primary end point, state
the required sample size (and how it was
determined) and recruitment target
(accounting for expected loss to follow-up).
If sample size is not established based on the
PRO end point, then discuss the power of
the principal PRO analyses.
Recruitment 15 Strategies for achieving adequate
participant enrollment to reach target
sample size
Methods: Assignment of Interventions (for Clinical Trials)
Allocation
Sequence
generation
16a Method of generating the allocation
sequence (eg, computer-generated random
numbers), and list of any factors for
stratification. To reduce predictability
of a random sequence, details of any
planned restriction (eg, blocking)
should be provided in a separate
document that is unavailable to those
who enroll participants or assign
interventions.
Allocation
concealment
mechanism
16b Mechanism of implementing the allocation
sequence (eg, central telephone;
sequentially numbered, opaque, sealed
envelopes), describing any steps
to conceal the sequence until interventions
are assigned
Implementation 16c Who will generate the allocation sequence,
who will enroll participants, and who will
assign participants
to interventions
Blinding
(masking)
17a Who will be blinded after assignment
to interventions (eg, trial participants, care
providers, outcome assessors,
data analysts) and how
17b If blinded, circumstances under which
unblinding is permissible and procedure for
revealing a participant’s allocated
intervention during the trial
(continued)
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Table. SPIRIT 2013 and SPIRIT-PRO Extension Checklist: Recommended Items to Address in a Clinical Trial Protocola (continued)
SPIRIT Section
SPIRIT
Item No. SPIRIT Item Description
SPIRIT-PRO
Item No.
SPIRIT-PRO Extension
or Elaboration Item Description
Addressed
on Page No.b
Methods: Data Collection, Management, and Analysis
Data collection
methods
18a Plans for assessment and collection
of outcome, baseline, and other trial
data, including any related processes to
promote data quality (eg, duplicate
measurements, training of assessors)
and description of study instruments
(eg, questionnaires, laboratory tests)
along with their reliability and validity,
if known; reference to where
data collection forms can be found,
if not in the protocol
SPIRIT-18a
(i)-PRO
Extension
Justify the PRO instrument to be used and
describe domains, number of items, recall
period, and instrument scaling and scoring
(eg, range and direction of scores indicating
a good or poor outcome). Evidence of PRO
instrument measurement properties,
interpretation guidelines, and patient
acceptability and burden should be provided
or cited if available, ideally in the population
of interest. State whether the measure
will be used in accordance with any user
manual and specify and justify deviations
if planned.
SPIRIT-18a
(ii)-PRO
Extension
Include a data collection plan outlining
the permitted mode(s) of administration
(eg, paper, telephone, electronic, other) and
setting (eg, clinic, home, other).
SPIRIT-18a
(iii)-PRO
Extension
Specify whether more than 1 language
version will be used and state whether
translated versions have been developed
using currently recommended methods.
SPIRIT-18a
(iv)-PRO
Extension
When the trial context requires someone
other than a trial participant to answer
on his or her behalf (a proxy-reported
outcome), state and justify the use
of a proxy respondent. Provide or cite
evidence of the validity of proxy assessment
if available.
18b Plans to promote participant retention and
complete follow-up, including list of
any outcome data to be collected for
participants who discontinue or deviate
from intervention protocols
SPIRIT-18b
(i)-PRO
Extension
Specify PRO data collection and
management strategies for minimizing
avoidable missing data.
SPIRIT-18b
(ii)-PRO
Elaboration
Describe the process of PRO assessment
for participants who discontinue
or deviate from the assigned
intervention protocol.
Data
management
19 Plans for data entry, coding, security,
and storage, including any related processes
to promote data quality (eg, double data
entry; range checks for data values);
reference to where details of data
management procedures can be found,
if not in the protocol
Statistical
methods
20a Statistical methods for analyzing
primary and secondary outcomes.
Reference to where other details of the
statistical analysis plan can be found,
if not in the protocol
SPIRIT-
20a-PRO
Elaboration
State PRO analysis methods, including
any plans for addressing
multiplicity/type I (α) error.
20b Methods for any additional analyses
(eg, subgroup and adjusted analyses)
20c Definition of analysis population
relating to protocol nonadherence
(eg, as randomized analysis) and any
statistical methods to handle missing data
(eg, multiple imputation)
SPIRIT-
20c-PRO
Elaboration
State how missing data will be described
and outline the methods for handling
missing items or entire assessments
(eg, approach to imputation and sensitivity
analyses).
Methods: Monitoring
21a Composition of data monitoring committee;
summary of its role and reporting structure;
statement of whether it is independent
from the sponsor and competing interests;
and reference to where further details
about its charter can be found, if not
in the protocol (alternatively, an explanation
of why a data monitoring committee
is not needed)
21b Description of any interim analyses
and stopping guidelines, including
who will have access to these interim
results and make the final decision
to terminate the trial
(continued)
Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols Special Communication Clinical Review& Education
jama.com (Reprinted) JAMA February 6, 2018 Volume 319, Number 5 489
© 2018 American Medical Association. All rights reserved.
Downloaded From:  by a University of Birmingham User  on 04/10/2018
Table. SPIRIT 2013 and SPIRIT-PRO Extension Checklist: Recommended Items to Address in a Clinical Trial Protocola (continued)
SPIRIT Section
SPIRIT
Item No. SPIRIT Item Description
SPIRIT-PRO
Item No.
SPIRIT-PRO Extension
or Elaboration Item Description
Addressed
on Page No.b
Harms 22 Plans for collecting, assessing, reporting,
and managing solicited and spontaneously
reported adverse events and other
unintended effects of trial interventions
or trial conduct
SPIRIT-
22-PRO
Extension
State whether or not PRO data will be
monitored during the study to inform the
clinical care of individual trial participants
and, if so, how this will be managed in
a standardized way. Describe how this
process will be explained to participants;
eg, in the participant information sheet and
consent form.
Auditing 23 Frequency and procedures for auditing trial
conduct, if any, and whether the process
will be independent from investigators
and sponsor(s)
Ethics and Dissemination
Research ethics
approval
24 Plans for seeking research ethics
committee/institutional review board
approval
Protocol
amendments
25 Plans for communicating important protocol
modifications (eg, changes to eligibility
criteria, outcomes, analyses) to relevant
parties (eg, investigators, research ethics
committees/institutional review boards,
trial participants, trial registries,
journals, regulators)
Consent or
assent
26a Who will obtain informed consent
or assent from potential trial participants
or authorized surrogates and how
(see item 32)
26b Additional consent provisions for collection
and use of participant data and biological
specimens in ancillary studies, if applicable
Confidentiality 27 How personal information about potential
and enrolled participants will be collected,
shared, and maintained to protect
confidentiality before, during, and after
the trial
Declaration of
interests
28 Financial and other competing interests for
principal investigators for the overall trial
and each study site
Access to data 29 Statement of who will have access to the
final trial data set and disclosure of
contractual agreements that limit such
access for investigators
Ancillary and
posttrial care
30 Provisions, if any, for ancillary and posttrial
care and for compensation
to those who are harmed by
trial participation
Dissemination
policy
31a Plans for investigators and sponsor(s) to
communicate trial results to participants,
health care professionals, the public, and
other relevant groups (eg, via publication,
reporting in results databases, or other
data-sharing arrangements), including any
publication restrictions
31b Authorship eligibility guidelines and any
intended use of professional writers
31c Plans, if any, for granting public access to
the full protocol, participant-level data set,
and statistical code
Appendixes
Informed
consent
materials
32 Model consent form and other related
documentation given to participants and
authorized surrogates
Biological
specimens
33 Plans for collection, laboratory evaluation,
and storage of biological specimens for
genetic or molecular analysis in the current
trial and for future use in ancillary studies,
if applicable
Abbreviations: SPIRIT, Standard Protocol Items: Recommendations for
Interventional Trials; PRO, patient-reported outcome.
a It is strongly recommended that this checklist be read in conjunction
with the SPIRIT 2013 Explanation & Elaboration for important clarification
on the items.1,2,20 Amendments to the protocol should be tracked and dated.
The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative
Commons “Attribution-NonCommercial-NoDerivs 3.0 Unported” license
and is reproduced with permission.
b Indicates page numbers to be completed by authors during protocol
development.
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to randomizationhelpsensureanunbiasedbaselineassessment,and
if specifiedasaneligibility criterion,ensuresdatacompleteness.This
is important because baseline PRO data are often used as a covari-
ate in analyses and are essential to calculating change from base-
line.CompletionofPROsprior to clinical assessments (as thesemay
influence patient responses) and standardization of the order of
questionnaire administration are advised to help reduce measure-
ment error.24 Allowable timewindows for each scheduled PRO as-
sessmentshouldbespecifiedtoensure thatPROdatacollectioncap-
tures the effect of the clinical event(s) of interest.
SPIRIT-14-PRO Elaboration: When a PRO is the primary end
point, state the required sample size (and how it was deter-
mined) and recruitment target (accounting for expected loss to
follow-up). If sample size isnotestablishedbasedon thePROend
point, then discuss the power of the principal PRO analyses.
Explanation: In studies in which PROs are the primary out-
come or end point, the target sample size will generally be based
on an a priori sample size calculation for that end point.23 Ideally,
the criteria for clinical significance (eg, minimal important differ-
ence, responder definition) should be specified when known.25,26
If PROs are a secondary end point, researchers should specify
whether the sample size provides sufficient power to test the prin-
cipal PRO hypotheses.23
Methods: Data Collection, Management, and Analysis
SPIRIT-18a(i)-PROExtension:JustifythePROinstrumenttobeused
and describe domains, number of items, recall period, instru-
ment scaling and scoring (eg, range and direction of scores indi-
catingagoodorpooroutcome).EvidenceofPROinstrumentmea-
surement properties, interpretation guidelines, and patient
acceptability and burden should be provided or cited if available,
ideally in the population of interest. State whether the measure
will be used in accordance with any user manual and specify and
justify deviations if planned.
Explanation: The selection of PROs to be used in a clinical trial
requires careful consideration. Ideally, the measure should be
validated in the target population.27 Consideration should be
given to the number of questionnaires to be used, acceptability of
the questions, and the likely patient burden (eg, time taken for
completion, cognitive burden, emotional burden). Justification
for the measures selected will help trial personnel understand
why specific measures are being used.10 Questionnaires should
be used in accordance with any existing user manuals to promote
data quality and ensure standardized scoring, and any deviations
should be described.
SPIRIT-18a(ii)-PRO Extension: Include a data collection plan
outliningthepermittedmode(s)ofadministration(eg,paper, tele-
phone, electronic, other) and setting (eg, clinic, home, other).
Explanation: It is important that both research personnel and
trial participants understand how, when, and where PRO data will
be collected in the study. Increasingly, electronic PRO assessment
is undertaken in trials, so evidence of equivalence between differ-
ent modes of administration should be considered.28 If electronic
PROmeasures containonlyminormodificationswith respect to the
paper-basedversions,usability testingandcognitivedebriefingmay
provide sufficient evidenceofequivalence.28,29Thesetting forPRO
data collection shouldbedescribedandstandardizedacross trial in-
tervention groups and sites.
SPIRIT-18a(iii)-PROExtension:Specifywhethermorethan1 lan-
guage version will be used and state whether translated versions
have been developed using currently recommendedmethods.
Explanation:Multinational trials, or national trials involving par-
ticipants with different languages, require measures that have
been translated and culturally adapted where needed using appro-
priate methodology.11,30 This may influence the selection of mea-
sure to be used because inclusion of a wide range of participants
can help ensure the generalizability of trial results. Plans to use
translated versions should be specified in the protocol, citing refer-
ences when available.
SPIRIT-18a(iv)-PRO Extension: When the trial context re-
quires someone other than a trial participant to answer on his or
her behalf (a proxy-reported outcome), state and justify the use
of a proxy respondent. Provide or cite evidence of the validity of
proxy assessment if available.
Explanation: Insomecontexts, suchastrials involvingyoungchil-
dren or cognitively impaired participants, it may be necessary for
someone other than a trial participant to respond on that partici-
pant’s behalf. Clear justification and specification of proxy report-
ing in theprotocol allowsexternal reviewers toassesspotential bias
and facilitates trial reporting in accordance with CONSORT-PRO.17
Evidenceof the size anddirectionofproxybias is a keyaspectof the
validity of proxy versions of PRO measures, informing valid inter-
pretation, and comparison of results. The European Medicines
Agency states that “in general proxy reporting should be avoided,
unless theuseof suchproxy ratersmaybe theonly effectivemeans
ofobtaining information thatmightotherwisebe lost.”5TheUSFood
and Drug Administration also discourages the use of proxy-
reported outcomes to inform labeling claims, recommending ob-
server reports instead.4
SPIRIT-18b(i)-PRO Extension: Specify PRO data collection
and management strategies for minimizing avoidable mis-
sing data.
Explanation: Missing data are a particular problem for PROs
because participants with the poorest outcomes in a trial often
are those who do not complete planned PRO assessments, and
data cannot be obtained retrospectively beyond the time frame
of interest or frommedical records. This is a potentially significant
source of bias and may reduce trial power.31 It is important to
note that not all missing PRO data are avoidable: patients have
the right to decide not to complete questionnaires. Common rea-
sons for avoidable missing PRO data are administrative errors,
lack of explanation of the importance of PRO data, and overly
burdensome questionnaires. Addressing these in the protocol
should help minimize avoidable missing data. A recent systematic
review provides a range of design, implementation, and reporting
strategies to help minimize and address missing PRO data.22
Examples of protocol content include ensuring that PRO end
points and hypotheses are clearly defined and scientifically com-
pelling, providing a rationale for PRO assessment, clearly specify-
ing the PRO assessment time points, defining acceptable PRO
assessment time windows, aligning PRO assessment time points
to clinic visits (if clinically informative), minimizing patient bur-
den, and specifying the importance of complete PRO data.22
SPIRIT-18b(ii)-PROElaboration: Describe the process of PRO
assessment for participantswhodiscontinue or deviate from the
assigned intervention protocol.
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Explanation:A clear plan for collection of PROs for trial partici-
pants who withdraw early from a study or who discontinue the in-
tervention helps minimize bias,32 ensures that staff collect all re-
quired PRO data in a standardized and timely way, and may assist
ethical appraisal of the study.
SPIRIT-20a-PRO Elaboration: State PRO analysis methods,
including any plans for addressingmultiplicity/type I (α) error.
Explanation: Many questionnaires, such as health-related
quality-of-life measures, are multidimensional and therefore may
yield several summary scores (eg, multiple domains and an overall
score). Furthermore, PROs are usually assessed at multiple time
points. Statistical analysis of all domains and time points implies
multiple hypothesis testing, which inflates the probability of
false-positive results (type I error).23 This can be contained by
prespecifying the key PRO domain(s) or overall score of interest
and the principal time point(s). Any plans to address multiplicity,
such as stepwise or sequential analyses, whereby multiple end
points are tested in a defined sequence that contains the overall
type I error to the desired level, or conventional nonhierarchical
methods (eg, Bonferroni correction), should be specified a
priori.4 The protocol should either fully address these issues or
provide a summary with reference to where full details can be
found (eg, in the statistical analysis plan).
SPIRIT-20c-PRO Elaboration: State how missing data will
be described andoutline themethods for handlingmissing items
or entire assessments (eg, approach to imputation and sensitiv-
ity analyses).
Explanation: There are 2 levels ofmissing PROdata: (1) patient
completion of some but not all items within an instrument and
(2) absence of the entire PRO assessment. Whether and how
missing items should be imputed is usually specified in an instru-
ment’s scoringalgorithm.WhenentirePROassessmentsaremissed,
analysis requires assumptions about why those data were missing
(ie, themissingdatamechanism). There are a rangeof statistical ap-
proaches, each with specific assumptions. Common methods in-
clude complete case analysis, imputation (various approaches),
a range ofmaximum likelihoodmodeling approaches, and sensitiv-
ity analysis.32 Inappropriate method selection may lead to poten-
tially biased and misleading results.22,32 The protocol should ac-
knowledge and summarize these issues, with full details provided
in the statistical analysis plan.
Methods: Monitoring
SPIRIT-22-PRO Extension: State whether or not PRO data will be
monitored during the study to inform the clinical care of indi-
vidual trialparticipantsand, ifso,howthiswillbemanagedinastan-
dardizedway. Describe how this processwill be explained to par-
ticipants;eg, intheparticipant informationsheetandconsentform.
Explanation: Evidence suggests that monitoring and manage-
mentofPROalerts (psychologicaldistressorphysical symptomsevi-
dent from PRO responses that may require an immediate re-
sponse) vary across andwithin trials.10,11,33 To protect the interests
of trial participants and minimize potential bias, it is important to
specify plans formonitoring.34 Ifmonitoring is not planned (for ex-
ample, in a low-risk study in which alerts are not anticipated), this
should also be briefly stated in the protocol, the participant infor-
mation sheet, and the consent form. Alternative support mecha-
nisms for patients should be outlined.
Supplementary Trial Documents
Supplement 3 outlines additional items recommended for inclu-
sion inother trialdocumentation, suchas thestatistical analysisplan,
participant information sheet, and training and guidance docu-
ments for staff.
Discussion
The SPIRIT-PRO Extension provides international consensus-
based guidance on PRO-specific information that should be in-
cluded in clinical trial protocols. It comprises 16 items: 5 elabora-
tions toexistingSPIRIT2013 items in thecontextofPROsand 11new
extensions for use alongside the existing SPIRIT 2013 guidance.1,2
It is important tonotethat theseareminimumrequirementsandthat
there may be value in including additional items in the protocols,
in supplementary information,or inboth, asoutlined inSupplement
3. Although this guidance has been developed for trials for which
PROs are a primary or key secondary outcome, research groups
that create protocols are encouraged to consider use of this guid-
ance in all trials or clinical research studies in which PROs are col-
lected, including if PROs are exploratory end points. The guidance
does not aim to be prescriptive regarding how information should
be included, as thismayvarydependingon the research settingand
local requirements. Further details of empirical evidenceunderpin-
ning theSPIRIT-PRO itemsandexamples for implementationwill be
provided in a future publication on the PROlearn35 and SPIRIT
Initiative20 websites and will be facilitated through further devel-
opment of the SPIRIT 2013 implementation tool SEPTRE20 (SPIRIT
Electronic Protocol Tool and Resource) and through dissemination
via international partners (eAppendix inSupplement 1). Inclusionof
PRO-specificprotocol contentwill facilitateappraisal of thePROele-
ments by funders, reviewers, research ethics committees, and pa-
tient partners. The SPIRIT-PROExtension is intended to encourage
and facilitate careful planning of PRO components of trials and
thereby improvePROtrial design. Consequently, this is expected to
help staff and patients understand the rationale for PRO assess-
ment, improve PRO data completeness and quality, facilitate high-
quality analysis and reporting, andultimately improve thequalityof
the global PRO evidence base.
To maximize the benefit of PRO data in policy and in practice,
it is recommended that careful consideration be given to the selec-
tionof outcomesandmeasures,36,37 analysis of PROdata,4,5,38 and
transparent reporting in accordance with CONSORT-PRO.17 Pa-
tient and public involvement in all of these aspects can help ensure
that PRO selection and application is transparent, relevant, and
acceptable.39,40 Consistent with this philosophy, patient partners
havebeen involved in all aspects of the development of the SPIRIT-
PROExtension.39,40Ultimately,high-qualityPROtrial resultswillhelp
ensure that patients’ voices are central to informing shared deci-
sion making, labeling claims, clinical guidelines, and health policy,
making patient-centered care a reality.
This study has several limitations. First, as the international
stakeholder survey included an anonymized nonprobability
sample, we were unable to determine either the level or charac-
teristics of nonresponders, meaning that the results of the survey
could be affected by nonresponse bias. Second, respondents
to the stakeholder survey were self-selecting and Delphi and
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consensus meeting participants were purposively sampled based
on their roles and expertise relating to PROs. Participants are
therefore more likely to have more knowledge relating to PROs
than broader research personnel. Third, the systematic review
underpinning the process was conducted in 2013; however,
throughout the guideline development process, the expert Delphi
and consensus meeting participants are encouraged to highlight
any additional relevant publications.
Conclusions
TheSPIRIT-PROguidelinesprovide recommendations for items that
shouldbe addressed and included in clinical trial protocols inwhich
PROs are a primary or key secondary outcome. Improveddesign of
clinical trials includingPROscouldhelpensurehigh-qualitydata that
may inform patient-centered care.
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